Bharat Biotech was established in the year 1996 by Dr. Krishna M. Ella and Mrs. Suchitra K. Ella, with a vision to generate innovative technologies with a strong backbone of intellectual capital for the manufacture of unique vaccines and biotherapeutics. Today, Bharat Biotech is a multidimensional biotechnology company specializing in product-oriented research and development leading to the manufacture of vaccines and biotherapeutics with global IPRs associated to its products.

The Bhoomi Pooja (Ground-breaking ceremony) was truly a ground breaking event, not just for Bharat but for Genome Valley, Hyderabad too – Bharat was the first plant to come up here.

Dr. Krishna Ella, alumnus of the Universities' of Wisconsin and Hawaii had realized his dream of setting up a world class facility in India. As this dream was taking concrete shape, the Ellas with other like minded scientists embarked on a mission to address some of Asia's regional health problems. The first Milestone came in the form of launching the world's first Cesium Chloride free Hepatitis B vaccine, Revac-B. Revac-B was launched in October 1998.

Bharat's second product was launched in May 2001. BIOGIT, which was India 's first Probiotic Yeast product to counter diarrhea.

In May 2003 Bharat launched TYPBAR. The launch of TYPBAR was also a great success for Bharat as it was India's first new generation vaccine against Typhoid. This marked the next Milestone in Bharat Biotech's goal to eradicate tropical diseases in developing countries.

Bharat is also the first Indian company to receive two grants from the Bill & Melinda Gates Foundation through PATH (Program for Appropriate Technologies in Health) to develop two new vaccines; against Malaria (October 2001) and Rotavirus (June 2002).

Getting the first
BBIL has notched up several firsts to its credit. It is the first Company:

• in the world to launch Cesium Chloride Free Recombinant Hepatitis-B Vaccine - Revac-B
• in India to launch Probiotic Yeast - BIOGIT
• in India to launch Recombinant Streptokinase - INDIKINASE
• in India to launch Zinc based ORS (based on WHO approved formula) - ZELECT
• in India to launch new generation Typhoid vaccine - TYPBAR
• in India to launch Recombinant Human Epidermal Growth Factor - REGEN-D
• Indian Biopharma Company approved by Korean FDA
• Indian company to get a Biotech Molecule patented - BH-005 against Staphylococcal infection
• in India to get two grants through CVP-PATH (Program for Appropriate Technologies in Health) from the Bill & Melinda Gates Foundation to develop two new vaccines under
  • Children's Vaccine Program (CVP) for Rotavirus
  • Malaria Vaccine Initiative (MVI) for Malaria